Division of Kidney and Pancreas Transplantation, Department of Surgery, University of Miami, Miller School of Medicine, 1801 NW 9th Ave., 5th Fl., Miami, FL 33136, USA.
Clin Transplant. 2011 Mar-Apr;25(2):E132-5. doi: 10.1111/j.1399-0012.2010.01360.x. Epub 2010 Nov 17.
An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n = 88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1 mg/kg) (n = 27) or thymoglobulin alone (4-7 doses; 1 mg/kg) (n = 23). SPK recipients received daclizumab (two doses; 1 mg/kg) in addition to thymoglobulin (five doses; 1 mg/kg). The return of peripheral blood CD25+ cells was delayed for 45 d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.
在胰肾联合（SPK）移植受者中，添加抗 CD25 单克隆抗体与胸腺球蛋白联合进行诱导治疗。通过流式细胞术分析，评估了 SPK（n = 88）和肾移植（KT）受者外周血中的 T 细胞亚群，包括 CD3 和 CD25。用达利珠单抗（抗 CD25）（五剂；1mg/kg）（n = 27）或单独用胸腺球蛋白（四至七剂；1mg/kg）（n = 23）治疗 KT 受者。SPK 受者在接受胸腺球蛋白（五剂；1mg/kg）的同时还接受了达利珠单抗（两剂；1mg/kg）。与仅接受胸腺球蛋白的 KT 受者相比，添加抗 CD25 至胸腺球蛋白的 SPK 受者，其外周血 CD25+细胞在移植后 45 天内恢复延迟。该策略可能导致实体器官移植时同种异体（供体特异性）T 效应细胞减少。
